LIFE BioCEEd has made an investment to support the development of a groundbreaking, non-invasive blood test for multiple myeloma, aiming to enhance early detection and improve patient care.
Information on the Target
LIFE BioCEEd a.s. is a pioneering venture capital entity based in Ostrava, Czech Republic, specializing in medical investments aimed at enhancing healthspan and lifespan for individuals. The company focuses on innovative areas such as regenerative medicine and advanced therapeutic technologies, enabling breakthroughs that could transform patient care and health outcomes. With a mission centered on improving well-being through scientific advancements, LIFE BioCEEd seeks to leverage its resources and expertise for impactful medical developments.
Recently, LIFE BioCEEd has made significant strides in the healthcare sector, including its participation in the Global Health Exhibition 2025 held in Riyadh, Saudi Arabia. The company's CEO, Stefan Savic, emphasized the importance of the Longevity Economy, marking it as a vital investment frontier where improved quality of life is a primary objective alongside life extension.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Target’s Specific Country
The healthcare industry in the Czech Republic has seen substantial growth and evolution over the past two decades, particularly in fields such as biotechnology and regenerative medicine. This growth is fueled by increased investment in research an
Similar Deals
LIFE BioCEEd
invested in
Wrocław University of Science and Technology
in 2025
in a Other VC deal